





Supplementary Figure 1. Mean scores at each visit through week 24 for (A) Patient Global Assessment (PtGA), (B) Pain Visual Analogue Scale (Pain VAS), (C) Health Assessment Questionnaire-Disability Index (HAQ-DI), (D) FACIT-Fatigue (FACIT-F)



● Placebo + csDMARDs ▲ Sarilumab 200 mg q2w + csDMARDs ■ Sarilumab 150 mg q2w + csDMARDs


(A) * P < 0.01 and †P ≤ 0.0001 versus placebo. All p-values are nominal.

(B) * P < 0.05, †P ≤ 0.0001, and ‡P < 0.001 versus placebo. All p-values are nominal. (C) * P < 0.05, †P < 0.001, and ‡P ≤ 0.0001 versus placebo. Only weeks 12 and 24 were in testing hierarchy; all other p-values are nominal. (D) * P < 0.05, †P < 0.001, and ‡P ≤ 0.0001 versus placebo. All p-values are nominal; Week 24 was in testing hierarchy but was below hierarchy break.

csDMARDs, conventional synthetic disease-modifying anti-rheumatic drugs.

Supplementary Figure 2. Post hoc analysis of percentage of patients reporting scores \geq Normative Values on FACIT-F and SF-36 at baseline and week 24.

*** $p < 0.05$ versus placebo.**



FACIT-F, Functional Assessment of Chronic Illness Therapy–Fatigue scale; SF-36, Short Form 36 Health Survey version 2 (PF, Physical Functioning; RP, Role Physical; BP, Bodily Pain; GH, General Health perceptions; VT, Vitality; SF, Social Functioning; RE, Role Emotional; MH, Mental Health).